Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
BACKGROUND
The purposes of this study were to determine the overall incidence of platelet refractoriness and alloimmunization among multiply transfused children on a medical oncology and bone marrow transplant service and to evaluate the effect of routine white cell reduction in blood components on that incidence.


METHODS
The platelet transfusion records of 128 consecutive children admitted to the hospital and requiring blood component support for the treatment of disease were evaluated retrospectively. Mean corrected count increments (CCIs) for each patient were calculated for all random-donor platelet transfusions given within 7 days of the routine weekly testings of the patient's serum for lymphocytotoxic antibodies (LCTAbs). Mean CCIs for HLA-matched platelet transfusions were calculated separately for the patients receiving them.


RESULTS
Thirty-one patients (24%) had or developed persistently positive LCTAbs (patient's serum reacted with > or = 3/10 panel lymphocytes); 22 (71%) of these patients had a mean CCI < 7.5 to random-donor platelet transfusions. In contrast, of the 97 patients with negative or transiently positive LCTAbs, only 25 (26%) had a mean CCI < 7.5. The overall incidence of platelet refractoriness (CCI < 7.5) was 37 percent. Patients with acute myelogenous leukemia had a significantly (p < 0.01) reduced incidence (17%) of low CCIs, with or without positive LCTAbs, as compared to patients with other malignant or nonmalignant disorders (41%). No difference in the incidence of LCTAbs or low CCIs was seen in patients undergoing allogeneic or autologous bone marrow transplant or receiving drug therapy only. Among the 24 patients who received HLA-matched platelets, only those with positive LCTAbs showed a significant improvement in CCIs over that achieved with random-donor platelet transfusions. Routine white cell reduction in red cell and platelet components with third-generation white cell filters was performed prior to transfusion in 73 of the patients. There was no significant difference between the incidence of LCTAbs and/or low CCIs in this group and that in the 55 children receiving unfiltered transfusions.


CONCLUSIONS
Alloimmunization and platelet refractoriness occur in pediatric oncology and bone marrow transplant patients, but the incidence--particularly in children with acute myelogenous leukemia--appears to be low. The detection of LCTAbs predicts a poor response to random-donor platelet transfusion, but most such patients show improved CCIs with HLA-matched platelets. Routine use of white cell-reduction filters has thus far failed to eliminate alloimmunization in children requiring prolonged blood component support.
Hogge
D E
DE
Cell Separator Unit, Vancouver Hospital and Health Sciences Centre, British Columbia, Canada.
McConnell
M
M
Jacobson
C
C
Sutherland
H J
HJ
Benny
W B
WB
Massing
B G
BG
D000293:Adolescent; D000961:Antilymphocyte Serum / Q000276:immunology*; D001792:Blood Platelets / Q000473:pathology*; D016026:Bone Marrow Transplantation / Q000473:pathology*; D002469:Cell Separation / Q000379:methods; D002648:Child; D002675:Child, Preschool; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006648:Histocompatibility; D006801:Humans; D007223:Infant; D007518:Isoantibodies / Q000276:immunology*; D007962:Leukocytes / Q000276:immunology; D008297:Male; D017713:Platelet Transfusion / Q000379:methods*; D012189:Retrospective Studies
D000961:Antilymphocyte Serum; D006680:HLA Antigens; D007518:Isoantibodies